Loading…
Reported covered position: n/a
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expanding Seniors Access to Mental Health Services Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Expanding Seniors Access to Mental Health Services Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2025 · third_quarter · Q3
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Source: Senate LDA
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Expanding Seniors Access to Mental Health Services Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Reserved for the Speaker.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Reserved for the Speaker.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing. Issues related to the funding of HHS blood and plasma awareness campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates. Issues related to the funding of HHS blood and plasma awareness campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
Share the Savings with Seniors Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2025 · second_quarter · Q2
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2025 · first_quarter · Q1
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Issues relating to tariffs and the importation of plasma-derived medicines, plasma intermediates, and materials necessary to collect source plasma donations and manufacture plasma derived-medicines.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · third_quarter · Q3
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · second_quarter · Q2
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · first_quarter · Q1
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · third_quarter · Q3
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates. Issues related to the funding of HHS blood and plasma awareness campaign.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · second_quarter · Q2
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing. Issues related to the funding of HHS blood and plasma awareness campaign.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · first_quarter · Q1
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2022 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)